Companies Kestra Medical Technologies
Kestra Medical Technologies (KMTS): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kestra Medical Technologies’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $757,564FY2024
- $18,890,730FY2025
- $7,501,904FY2026
CEO total pay was $7,501,904 in fiscal 2026, down from $18,890,730 in fiscal 2025.
FY2026: salary $765,000 · bonus $0 · stock awards $5,722,937 · option awards $0
Executives and directors
Brian Webster · CEOAl Ford · CCOTraci Umberger · General CounselVaseem Mahboob · CFOChristopher Gordon · Former director (through FY2026)Conor Hanley · Independent DirectorElizabeth Kwo, M.D · Independent DirectorJeffrey Schwartz · Chair of the BoardKevin Reilly · Independent DirectorMary Kay Ladone · Independent DirectorMaxwell Bikoff · Former director (through FY2026)Raymond W. Cohen · Independent DirectorToby AuWerter · Former director (through FY2026)
Frequently asked questions
Who was the highest-paid executive at Kestra Medical Technologies in fiscal 2026?
As disclosed, Brian Webster (President, Chief Executive Officer & Director) was the highest-paid executive at Kestra Medical Technologies in fiscal 2026, with total compensation of $7,501,904.
How much does Kestra Medical Technologies spend in total on board compensation for fiscal 2026?
As disclosed, Kestra Medical Technologies reported total board compensation of $1,707,675 for fiscal 2026.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian Webster | $765,000 | $0 | $5,722,937 | $0 | $918,000 | $0 | $95,966 | $7,501,904 |
| President, Chief Executive Officer & Director | ||||||||
| Traci Umberger | 500,000 | 0 | 1,907,662 | 0 | 360,000 | 0 | 93,756 | 2,861,418 |
| General Counsel, Chief Administrative Officer & Director | ||||||||
| Al Ford | 500,000 | 0 | 1,907,662 | 0 | 360,000 | 0 | 24,424 | 2,792,086 |
| Chief Commercial Officer | ||||||||
| Vaseem Mahboob | 470,000 | 0 | 1,430,747 | 0 | 338,400 | 0 | 28,197 | 2,267,344 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Brian Webster | $7,501,904 | $18,890,730 | $757,564 | ↓ −11,388,826 |
| Traci Umberger | 2,861,418 | 6,067,589 | 498,289 | ↓ −3,206,171 |
| Al Ford | 2,792,086 | — | — | — |
| Vaseem Mahboob | 2,267,344 | 2,323,082 | 530,176 | ↓ −55,738 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company seeks to foster a performance-oriented culture where individual performance is aligned with company objectives. A substantial majority of executives' realizable compensation is performance-based and varies with the achievement of Company financial objectives and changes in share price.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Radford |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Traci Umberger | RSU | 645,658 | — | $1 |
| Brian Webster | RSU | 1,965,098 | — | 3 |
| Kevin Reilly | RSU | 3,131,093 | — | 5 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey SchwartzIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) | $141,000 | $185,017 | $0 | — | $0 | $326,017 |
| Conor HanleyIndependent · Audit | 63,370 | 222,532 | 0 | — | 0 | 285,902 |
| Mary Kay LadoneIndependent · Audit (Chair) · Nominating and Corporate Governance | 91,000 | 185,017 | 0 | — | 0 | 276,017 |
| Raymond W. CohenIndependent · Audit · Compensation (Chair) | 90,000 | 185,017 | 0 | — | 0 | 275,017 |
| Kevin ReillyIndependent · Compensation | 69,000 | 185,007 | 0 | — | 0 | 254,007 |
| Elizabeth Kwo, M.DIndependent · Nominating and Corporate Governance | 42,500 | 185,017 | 0 | — | 0 | 227,517 |
| Maxwell BikoffIndependent · Not standing for re-election · Departed during FY | 18,000 | 0 | 0 | — | 7,537 | 25,537 |
| Christopher GordonIndependent · Not standing for re-election · Departed during FY | 15,000 | 0 | 0 | — | 6,161 | 21,161 |
| Toby AuWerterIndependent · Not standing for re-election · Departed during FY | 16,500 | 0 | 0 | — | 0 | 16,500 |
| Brian WebsterEmployee director | — | — | — | — | — | 0 |
| Traci S. UmbergerEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $185,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 18,000 / 12,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $546,370 |
| Equity awards (grant-date value) | $1,147,607 |
| All other compensation | $13,698 |
| Total cost of the board | $1,707,675 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kestra Medical Technologies as a peer
Companies that benchmark against KMTS
No companies currently name KMTS as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2026
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
SIBN SI-BONEIRTC iRhythm HoldingsLIVN LivaNovaCVRX CVRxRXST RxSightTCMD Tactile Systems TechnologySGHT Sight SciencesTMDX TransMedics GroupATRC AtriCureAXGN AxoGenINSP Inspire Medical SystemsCBLL CeribellBFLY Butterfly NetworkPRCT PROCEPT BioRoboticsLMAT LeMaitre VascularBVS BioventusSMLR Semler Scientific
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Procept BioRobotics | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | iRhythm Holdings | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 3 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 4 | AtriCure | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 5 | AxoGen | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 6 | LivaNova | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 7 | Inspire Medical Systems | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 8 | Kestra Medical Technologies | 2026 | Brian Webster | 765,000 | 5,722,937 | 0 | 918,000 | 7,501,904 |
| 9 | SI-Bone | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 10 | Butterfly Network | 2025 | Joseph DeVivo | 900,300 | 4,291,604 | 0 | 1,183,000 | 6,382,814 |
| 11 | RxSight | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 12 | Ceribell | 2025 | Xingjuan Chao | 639,000 | 1,707,132 | 1,574,179 | 619,313 | 4,565,821 |
| 13 | Bioventus | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 14 | CVRx | 2025 | Kevin Hykes | 660,533 | 1,270,080 | 1,516,896 | 444,492 | 3,905,801 |
| 15 | LeMaitre Vascular | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 16 | Tactile Systems Technology | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 17 | Sight Sciences | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| — | Semler Scientific | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kestra Medical Technologies | not disclosed | not disclosed | not disclosed | Aon Radford |
| AtriCure | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| AxoGen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Bioventus | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| Butterfly Network | 131.25% for Joseph DeVivo; 109.2% for Steven Cashman% | not disclosed | No | Pay Governance |
| Ceribell | not disclosed | not disclosed | not disclosed | Radford |
| CVRx | Kevin Hykes: 84%; Robert John: 66%; Philip Adamson: 84%% | Stock Options 50 · RSUs 50 | not disclosed | Aon |
| Inspire Medical Systems | 111.4% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Holdings | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LeMaitre Vascular | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| LivaNova | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Procept BioRobotics | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| RxSight | 32.18% | Option 100 | not disclosed | Aon |
| Semler Scientific | not disclosed | not disclosed | not disclosed | not disclosed |
| SI-Bone | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Sight Sciences | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| Tactile Systems Technology | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (34 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brian Webster. DEF 14A, filed 2026-07-28. Section “Executive Compensation” · page 23. As printed: 7,501,904. View filing ↗
- Section 01, Traci Umberger. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 2,861,418. View filing ↗
- Section 01, Al Ford. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 2,792,086. View filing ↗
- Section 01, Vaseem Mahboob. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 2,267,344. View filing ↗
- Section 08, Jeffrey Schwartz. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 326,017. View filing ↗
- Section 08, Conor Hanley. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 285,902. View filing ↗
- Section 08, Mary Kay Ladone. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 276,017. View filing ↗
- Section 08, Raymond W. Cohen. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 275,017. View filing ↗
- Section 08, Kevin Reilly. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 254,007. View filing ↗
- Section 08, Elizabeth Kwo, M.D. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 227,517. View filing ↗
- Section 08, Maxwell Bikoff. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 25,537. View filing ↗
- Section 08, Christopher Gordon. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 21,161. View filing ↗
- Section 08, Toby AuWerter. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 16,500. View filing ↗
- Section 08, Brian Webster. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Traci S. Umberger. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 546,370 + equity 1,147,607 + all other 13,698 = 1,707,675, summed across the director compensation table rows.
- Procept BioRobotics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics's own proxy. As printed: 16,783,853. View filing ↗
- iRhythm Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Holdings's own proxy. As printed: 11,003,163. View filing ↗
- TransMedics Group, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. View filing ↗
- AtriCure, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. View filing ↗
- AxoGen, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. View filing ↗
- LivaNova, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova's own proxy. As printed: 8,047,217. View filing ↗
- Inspire Medical Systems, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems's own proxy. As printed: 7,711,784. View filing ↗
- Kestra Medical Technologies (subject), Section 10b CEO total. DEF 14A, filed 2026-07-28. CEO total compensation as printed in Kestra Medical Technologies's own proxy. As printed: 7,501,904. View filing ↗
- SI-Bone, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in SI-Bone's own proxy. As printed: 7,453,235. View filing ↗
- Butterfly Network, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Butterfly Network's own proxy. As printed: 6,382,814. View filing ↗
- RxSight, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. View filing ↗
- Ceribell, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Ceribell's own proxy. As printed: 4,565,821. View filing ↗
- Bioventus, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bioventus's own proxy. As printed: 4,299,108. View filing ↗
- CVRx, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in CVRx's own proxy. As printed: 3,905,801. View filing ↗
- LeMaitre Vascular, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. View filing ↗
- Tactile Systems Technology, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology's own proxy. As printed: 3,466,916. View filing ↗
- Sight Sciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sight Sciences's own proxy. As printed: 2,005,608. View filing ↗